Literature DB >> 29372174

PRUNE Syndrome Is a New Neurodevelopmental Disorder: Report and Review.

Majid Alfadhel1, Marwan Nashabat1, Khalid Hundallah2, Amal Al Hashem3, Ahmed Alrumayyan4, Brahim Tabarki2.   

Abstract

PRUNE syndrome, or neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies (OMIM#617481), is a new rare autosomal recessive neurodevelopmental disease that is caused by homozygous or compound heterozygous mutation in PRUNE1 on chromosome 1q21. Here, We report on 12-month-old and 30-month-old girls from 2 unrelated Saudi families with typical presentations of PRUNE syndrome. Both patients had severe developmental delay, progressive microcephaly, and dysmorphic features. Brain magnetic resonance imaging showed slight thinning in the corpus callosum, mild frontal brain atrophy, and delayed myelination in one of the patients. Both patients had the same missense mutation in PRUNE1 (c.383G>A, p.Arg128Gln), which was not reported before in a homozygous state. We compared our patients to previously reported cases. In conclusion, We suggest that clinicians consider PRUNE syndrome in any child presenting with dysmorphic features, developmental delay, progressive microcephaly, central hypotonia, peripheral spasticity, delayed myelination, brain atrophy, and a thin corpus callosum.

Entities:  

Keywords:  PRUNE syndrome; PRUNE1; developmental delay; progressive microcephaly; spasticity

Year:  2018        PMID: 29372174      PMCID: PMC5768269          DOI: 10.1177/2329048X17752237

Source DB:  PubMed          Journal:  Child Neurol Open        ISSN: 2329-048X


The PRUNE1 gene is a member of the DHH (Asp-His-His) phosphoesterase group, which are the enzymes that break phosphoester bonds in a wide range of substrates.[1] Additionally, it has a role in cell migration.[2] Recently, it was shown that PRUNE plays a role in neuronal migration and proliferation, which was related back to its regulatory effect on microtubule polymerization. The change in tubulin dynamics could be related to the patientsmicrocephaly and other neurological derangements.[3] PRUNE syndrome, or neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies (OMIM#617481), is a new rare autosomal recessive neurodevelopmental disease that is caused by homozygous or compound heterozygous mutation in the PRUNE1 gene on chromosome 1q21.[4] It was first described by Karaca et al, who reported 4 patients from 4 different families. The patients had a distinct form of dysmorphic features and global developmental delay associated with microcephaly, central hypotonia, spastic quadriplegia, cerebral atrophy, and cerebellar atrophy. The main dysmorphic features were sloping forehead, flat nasal bridge, abnormal dentition, widely spaced teeth, micrognathia, and low-set ears. Several patients were noted to have seizures. This report was followed by 2 additional reports in 2017. The first reported 14 patients from different countries: Turkey, Saudi Arabia, United States, Oman, India, Iran, and Italy. Two of the 14 patients were reported by the same group in the previous study.[3,4] Costain et al[5] reported an additional patient with PRUNE1 mutation. These recent reports confirmed that PRUNE syndrome is pan-ethnic.[3,5] The diagnosis was confirmed in all reported patients by finding a homozygous or compound heterozygous mutation in the PRUNE1 gene. As this is a newly described disease, there are scarce data in the literature about clinical and radiological phenotypes. In this case report, We elaborate more on the clinical, radiological, and molecular findings of 2 unrelated Saudi probands with the PRUNE syndrome and compare our results to the previously reported cases. To the best of our knowledge, this is the first report in the literature to confirm a homozygous missense mutation (p.Arg128Gln) in the PRUNE1 gene and the fourth report in the literature to examine this new neurogenic disorder. In this report, We expanded the genotype of PRUNE syndrome.

Methods

Patients

This is a retrospective chart review of patients from genetics and neurology clinics at King Abdulaziz Medical City and Prince Sultan Medical Military City at Riyadh, Saudi Arabia.

Molecular Studies

This study was done at accredited laboratories using the following methods.

Patient 1

Targeted exome sequencing using genomic DNA from the patient’s specimen, the exonic regions, and flanking splice junctions of the genome were sequenced by massively parallel (NextGen) sequencing on an Illumina sequencing system with 100 base pair or greater paired-end reads. Reads were aligned to human genome build GRCH37UCSC hg19 and analyzed for sequence variants in the selected genes or regions of interest using a custom-developed analysis tool (Xome Analyzer). Capillary sequencing was used to confirm all potentially pathogenic variants identified. Segregation analysis was done to both parents after discovering the mutation in the index case.

Patient 2

Whole-exome sequencing was done to the index case and both parents: Approximately 37 Mb (214 405 exons) of the consensus coding sequences were enriched from fragmented genomic DNA by >340 000 probes designed against the human genome (Nextera Rapid Capture Exome, Illumina) and the generated library sequenced in an Illumina platform to an average coverage depth 70-100×. An end-to-end in-house bioinformatics pipeline including base calling, primary filtering of low quality reads and probable artifacts, and annotation of variants was applied. All disease-causing variants reported in HGMD and ClinVar as well as all variants with minor allele frequency of less than 1% in ExAC database are considered. Evaluation is focused on exons and intron boundaries ±20.

Literature Review

A thorough review of the literature for all reported PRUNE disease cases or mutations in PRUNE1 gene was done using a systematic search in PubMed database.

Case Report

Patient 1

Patient 1 was a full-term baby girl born by normal spontaneous vaginal delivery. She had a birth weight of 2.7 kg (−1.1 standard deviation [SD]), was 46 cm in length (−1.5 SD), had a head circumference of 33 cm (−0.5 SD), and had an Apgar score of 8 and 9 at 5 and 10 minutes, respectively. After delivery, she stayed in the hospital for 1 day due to jaundice. The first concern by the parents was at 1 year of age due to global developmental delay. At that time, she was unable to walk or crawl or even sit; she just laid in the bed and had no speech. Then, she was referred to a genetics service at 16 months of age for further evaluation, where her examination showed the following growth parameters: weight 8.8 kg (−0.8 SD), length 46 cm (−0.6 SD), and head circumference 44.5 cm (−1 SD). She had dysmorphic features (plagiocephaly, microcephaly, epicanthal folds, hypertelorism, flat nasal bridge, abnormal dentition, widely spaced teeth, micrognathia, low-set ears, and hirsutism; Figure 1A). A neurological examination showed central hypotonia and spastic quadriplegia with hyperreflexia and clonus. Other systemic examinations were unremarkable. Currently, on examination at 30 months, she continued to have progressive microcephaly (head circumference 45 cm [−2.1 SD], length 83 cm [−2.1 SD], and weight 10 kg [−2 SD]). Development was severely delayed as she could only sit with support, had inconsistent hand grasp, and produced sound without any words. She is functioning at the level of 6 months of age and continues to have central hypotonia and spastic quadriplegia with hyperreflexia and clonus. A study of her upper GI showed moderate to severe gastroesophageal reflux with no malrotation. A milk scan showed significantly delayed gastric emptying. The auditory brainstem response test was normal. An ophthalmology examination showed bilateral rudimentary iris strands. Brain magnetic resonance imaging (MRI) showed delayed myelination, slightly abnormal shape of the corpus callosum, and mild frontal cerebral atrophy (Figure 1B and C). A skeletal survey and echocardiogram were unremarkable. Extensive biochemical and molecular genetics investigations, including ammonia level, lactic acid, creatine kinase level, total homocysteine, acylcarnitine profile, urine organic acids, and chromosomal analysis, were unremarkable. CGH microarray showed multiple blocks of homozygous sequence encompassing 46 Mb (1.6%) of autosomal genomic length with no apparent chromosomal derangements. Targeted exome sequencing for these blocks showed a previously reported homozygous missense mutation in PRUNE1 gene (c.383G>A, p.Arg128Gln; NM_021222.1). Both parents were heterozygous for this mutation.
Figure 1.

A, Patient 1 dysmorphic features: plagiocephaly, microcephaly, epicanthal folds, hypertelorism, flat nasal bridge, abnormal dentition, widely spaced teeth, micrognathia, low-set ears, hirsutism, spasticity, and crossing legs. B, Brain MRI (patient 1), T1-weighted image, and sagittal section showing abnormal shape of the corpus callosum with thinning. C, Brain MRI (patient 1), T2-weighted image, and axial section showing mild brain atrophy mainly in the frontal lobe. MRI indicates magnetic resonance imaging.

A, Patient 1 dysmorphic features: plagiocephaly, microcephaly, epicanthal folds, hypertelorism, flat nasal bridge, abnormal dentition, widely spaced teeth, micrognathia, low-set ears, hirsutism, spasticity, and crossing legs. B, Brain MRI (patient 1), T1-weighted image, and sagittal section showing abnormal shape of the corpus callosum with thinning. C, Brain MRI (patient 1), T2-weighted image, and axial section showing mild brain atrophy mainly in the frontal lobe. MRI indicates magnetic resonance imaging.

Patient 2

Patient 2 was a full-term baby girl born by normal spontaneous vaginal delivery. Her birth weight was 2 kg (−3 SD), her length was 45.5 cm (−2 SD), her head circumference was 33 cm (−0.5 SD), and her Apgar scores were 8 and 9 at 5 and 10 minutes, respectively. Family history showed positive parental consanguinity. Additionally, 1 cousin died with similar phenotype. The patient showed severe global developmental delay, mainly in motor function: At 12 months of age, the patient was smiling and fixating but could not turn from side to side and had no grasp. There was no history of seizures. On examination, the growth parameters were as follows: weight 6.7 kg (−2.5 SD), length 67 cm (−2.5 SD), microcephaly was present, and head circumference 43 cm (−2.3 SD). Apart from the microcephaly, she did not have any other dysmorphic features. She was fixating, following, and smiling. There was axial hypotonia and appendicular spasticity with deep tendon reflexes +3. The ophthalmology examination was unremarkable. The MRI brain showed a slightly abnormally shaped corpus callosum and slightly prominent CSF spaces anteriorly with normal myelination. Magnetic resonance spectroscopy was unremarkable. Whole-exome sequencing showed homozygous mutation in the PRUNE1 gene: c.383G>A p.(Arg128Gln). Both parents were heterozygous for this mutation.

Discussion

Our report showed similar findings delineated by previous reports. Table 1 compared the clinical findings in this report with the former ones. In 19 children, all had the following cardinal features: severe global developmental delay, no speech, the patients just laid in the bed and did not acquire any milestones, appendicular hypotonia, and spastic quadriplegia, in addition to hyperreflexia, which was reported in the majority of the patients. Dysmorphic features, as mentioned above, were reported in all previous cases. Plagiocephaly and progressive microcephaly ranging between −2 and −6 SD were detected in 79% of the cases. Eye findings including congenital cataracts and optic atrophy were reported in approximately 21% of the cases. In this study, patient 1 had rudimentary iris strands, which was not reported previously. Further studies are needed to prove the correlation of PRUNE1 mutation with the described ocular phenotype. Approximately 50% of the patients had seizures, including generalized tonic-clonic seizures, myoclonic seizures, and infantile spasms. An electroencephalogram (EEG) was performed in 1 patient who had infantile spasms and showed a higher degree of hypsarrhythmia on the right posterior temporal region.[5] The patients presented herein had no seizures, and their EEGs were normal. One of our patients had gastroesophageal reflux, which was not reported previously.
Table 1.

Demographic and Clinical Data of the Presented Cases Compared to Previously Reported Cases.

Patient 1Patient 2Previously Reported CasesTotal (%)
Demographic
 Number of patients111719
 Number of families11911
 Age at evaluation (year)2.510.3-210.3-21
 Sex (M:F)0:10:17:107:12
 OriginSaudi ArabiaSaudi ArabiaTurkish, Saudi Arabia, United States, Oman, India, Iran, and Italy
 Racial ethnic backgrounda ArabArabArab, Turkish, and Oji-Cree
 ConsanguinityNoYes12/1713/19 (68.4%)
Clinical phenotypes
 Dysmorphic featuresYesNo17/1718/19 (94.7%)
 PlagiocephalyYesYes13/1715/19 (78.9%)
 Congenital cataractYesNo3/174/19 (21%)
 Optic atrophyNoNo2/172/19 (10.5%)
 Rudimentary iris strandsYesNo0/171/19 (5.2%)
 Global developmental delayYesYes17/1719/19 (100%)
 NonverbalYesYes17/1719/19 (100%)
 No independent ambulationYesYes17/1719/19 (100%)
 Progressive microcephalyYesYes16/1718/19 (94.7%)
 Axial hypotoniaYesYes17/1719/19 (100%)
 Spastic quadriplegiaYesYes16/1718/19 (94.7%)
 HyperreflexiaYesYes13/1715/19 (78.9)
 GERYesNoNA
 SeizureNoNo9/179/19 (47.3%)
Brain MRI
 Delayed myelinationYesNo15/1716/19 (84.2%)
 Thin corpus callosumAbnormal shapeAbnormal shape6/178/19 (42.1%)
 White matter diseaseNoNo6/176/19 (31.5%)
 Cerebral atrophyYesYes (mild)6/178/19 (42.1%)
 Cerebellar atrophyNoNo6/176/19 (31.5%)
Molecular findings
 Mutation in PRUNE1 genep.Arg128Glnp.Arg128Glnp.Asp30Asn, p.Pro54Thr, p.Asp106Asn, p.Arg297Trp, p.Gly174X
 Types of mutationHomozygous missenseHomozygous missenseHomozygous or compound heterozygous, missense or nonsense, in addition to one splice site mutation

Abbreviations: F, female; GER, gastroesophageal reflux; M, male; MRI, magnetic resonance imaging; NA, not available.

aThe racial ethnic background of the Italian, Iranian, and Indian patients are not available in the original report.

Demographic and Clinical Data of the Presented Cases Compared to Previously Reported Cases. Abbreviations: F, female; GER, gastroesophageal reflux; M, male; MRI, magnetic resonance imaging; NA, not available. aThe racial ethnic background of the Italian, Iranian, and Indian patients are not available in the original report. Radiological results display that most of the patients have delayed myelination, which is reported in 84.2% of the cases, and approximately one-third of the patients have a thin corpus callosum, white matter disease, and cerebral and cerebellar atrophy.[3-5] It is clear that PRUNE syndrome features are mainly neurological in nature, and this is partly explained by the fact that PRUNE1 is highly expressed in the brain and plays a significant role in neuronal cell proliferation, motility, and migration.[1] The significant similarity of the clinical phenotype indicates that all of the above features are distinctive components of this novel neurodevelopmental disorder. Several novel genes have been recently described with the following main features: intellectual disability, progressive microcephaly, spasticity, delayed myelination, and a thin corpus callosum. For example, the SLC1A4 gene defect was reported in 4 Ashkenazi Jews[6,7] and the RUSC2 gene defect was detected in 3 children from Saudi Arabia.[8] The newly described diseases expand the differential diagnosis of this phenotype (progressive microcephaly, intellectual disability, thin corpus callosum, and axial hypotonia with peripheral spasticity), which might include, for example, Aicardi syndrome, Amish microcephaly, Aicardi-Goutieres syndrome, and pyruvate dehydrogenase complex deficiency. For the first time in the literature, we have reported a homozygous missense variant (c.383G>A, p.Arg128Gln; NM_021222.1) in the PRUNE1 gene. This variant has been reported previously in a compound heterozygous state with a nonsense variant in 2 siblings with severe developmental delay, regression, seizure, microcephaly, and cerebral and cerebellar atrophy.[4] The in silico predictions for this variant were as follows: Polyphen2 predicted probably damaging with score at 0.994.[9] SIFT[10] predicted damaging with score at 0.027. Finally, MutationTaster[11] predicted disease-causing variant that might affect the protein features. Most of the previously reported cases have homozygous missense variants (90%). Only 1 patient had a splice site mutation, and another patient had compound heterozygous for missense and nonsense mutations.[4,5] The high rate of homozygous mutations can be explained by the elevated rate of consanguinity in the reported cohort. Interestingly, there have been no reported deletions, duplications, or homozygous nonsense mutations so far. Such observation may be due to the small reported sample size or the severity of the mutation may not be compatible with survival until birth. Subsequent larger studies are needed to determine a proper genotype–phenotype correlation. Most of the reported mutations were clustered in the DHH domain of the protein, except the p.Arg297Trp mutation, which is located in DHHA2 domain (Figure 2).
Figure 2.

PRUNE1 gene consists of 8 exons. PRUNE protein is composed of 453 amino acids. It harbors 2 domains DHH (20-172) and DHHA2 (215-359). Most of the described mutations so far are clustered in DHH domain.

PRUNE1 gene consists of 8 exons. PRUNE protein is composed of 453 amino acids. It harbors 2 domains DHH (20-172) and DHHA2 (215-359). Most of the described mutations so far are clustered in DHH domain. In conclusion, the authors want to alert clinicians to consider PRUNE syndrome in any child who presents with dysmorphic features, profound developmental delay, progressive microcephaly, central hypotonia, peripheral spasticity, delayed myelination, brain atrophy, and a thin corpus callosum. Animal model research are vital to understanding the pathophysiology of PRUNE syndrome, which may result in a better understanding of the disease in order to pave the way for future discovery of a treatment for this disorder.
  11 in total

1.  Predicting deleterious amino acid substitutions.

Authors:  P C Ng; S Henikoff
Journal:  Genome Res       Date:  2001-05       Impact factor: 9.043

2.  MutationTaster evaluates disease-causing potential of sequence alterations.

Authors:  Jana Marie Schwarz; Christian Rödelsperger; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2010-08       Impact factor: 28.547

3.  A homozygous mutation in SLC1A4 in siblings with severe intellectual disability and microcephaly.

Authors:  M Srour; F F Hamdan; Z Gan-Or; D Labuda; C Nassif; M Oskoui; M Gana-Weisz; A Orr-Urtreger; G A Rouleau; J L Michaud
Journal:  Clin Genet       Date:  2015-05-28       Impact factor: 4.438

4.  SLC1A4 mutations cause a novel disorder of intellectual disability, progressive microcephaly, spasticity and thin corpus callosum.

Authors:  G Heimer; D Marek-Yagel; E Eyal; O Barel; D Oz Levi; C Hoffmann; E K Ruzzo; E Ganelin-Cohen; D Lancet; E Pras; G Rechavi; A Nissenkorn; Y Anikster; D B Goldstein; B Ben Zeev
Journal:  Clin Genet       Date:  2015-07-28       Impact factor: 4.438

5.  Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions.

Authors:  Tsuyoshi Kobayashi; Shin-ichiro Hino; Naohide Oue; Toshimasa Asahara; Massimo Zollo; Wataru Yasui; Akira Kikuchi
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

6.  A method and server for predicting damaging missense mutations.

Authors:  Ivan A Adzhubei; Steffen Schmidt; Leonid Peshkin; Vasily E Ramensky; Anna Gerasimova; Peer Bork; Alexey S Kondrashov; Shamil R Sunyaev
Journal:  Nat Methods       Date:  2010-04       Impact factor: 28.547

7.  Loss-of-function mutation in RUSC2 causes intellectual disability and secondary microcephaly.

Authors:  Ali H Alwadei; Ruba Benini; Adel Mahmoud; Ali Alasmari; Erik-Jan Kamsteeg; Majid Alfadhel
Journal:  Dev Med Child Neurol       Date:  2016-09-09       Impact factor: 5.449

8.  Genes that Affect Brain Structure and Function Identified by Rare Variant Analyses of Mendelian Neurologic Disease.

Authors:  Ender Karaca; Tamar Harel; Davut Pehlivan; Shalini N Jhangiani; Tomasz Gambin; Zeynep Coban Akdemir; Claudia Gonzaga-Jauregui; Serkan Erdin; Yavuz Bayram; Ian M Campbell; Jill V Hunter; Mehmed M Atik; Hilde Van Esch; Bo Yuan; Wojciech Wiszniewski; Sedat Isikay; Gozde Yesil; Ozge O Yuregir; Sevcan Tug Bozdogan; Huseyin Aslan; Hatip Aydin; Tulay Tos; Ayse Aksoy; Darryl C De Vivo; Preti Jain; B Bilge Geckinli; Ozlem Sezer; Davut Gul; Burak Durmaz; Ozgur Cogulu; Ferda Ozkinay; Vehap Topcu; Sukru Candan; Alper Han Cebi; Mevlit Ikbal; Elif Yilmaz Gulec; Alper Gezdirici; Erkan Koparir; Fatma Ekici; Salih Coskun; Salih Cicek; Kadri Karaer; Asuman Koparir; Mehmet Bugrahan Duz; Emre Kirat; Elif Fenercioglu; Hakan Ulucan; Mehmet Seven; Tulay Guran; Nursel Elcioglu; Mahmut Selman Yildirim; Dilek Aktas; Mehmet Alikaşifoğlu; Mehmet Ture; Tahsin Yakut; John D Overton; Adnan Yuksel; Mustafa Ozen; Donna M Muzny; David R Adams; Eric Boerwinkle; Wendy K Chung; Richard A Gibbs; James R Lupski
Journal:  Neuron       Date:  2015-11-04       Impact factor: 17.173

9.  Evidence for interaction between human PRUNE and nm23-H1 NDPKinase.

Authors:  A Reymond; S Volorio; G Merla; M Al-Maghtheh; O Zuffardi; A Bulfone; A Ballabio; M Zollo
Journal:  Oncogene       Date:  1999-12-02       Impact factor: 9.867

10.  PRUNE is crucial for normal brain development and mutated in microcephaly with neurodevelopmental impairment.

Authors:  Massimo Zollo; Mustafa Ahmed; Veronica Ferrucci; Vincenzo Salpietro; Fatemeh Asadzadeh; Marianeve Carotenuto; Reza Maroofian; Ahmed Al-Amri; Royana Singh; Iolanda Scognamiglio; Majid Mojarrad; Luca Musella; Angela Duilio; Angela Di Somma; Ender Karaca; Anna Rajab; Aisha Al-Khayat; Tribhuvan Mohan Mohapatra; Atieh Eslahi; Farah Ashrafzadeh; Lettie E Rawlins; Rajniti Prasad; Rashmi Gupta; Preeti Kumari; Mona Srivastava; Flora Cozzolino; Sunil Kumar Rai; Maria Monti; Gaurav V Harlalka; Michael A Simpson; Philip Rich; Fatema Al-Salmi; Michael A Patton; Barry A Chioza; Stephanie Efthymiou; Francesca Granata; Gabriella Di Rosa; Sarah Wiethoff; Eugenia Borgione; Carmela Scuderi; Kshitij Mankad; Michael G Hanna; Piero Pucci; Henry Houlden; James R Lupski; Andrew H Crosby; Emma L Baple
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

View more
  2 in total

1.  Neurodevelopmental disorder with microcephaly, hypotonia, and variable brain anomalies in a consanguineous Iranian family is associated with a homozygous start loss variant in the PRUNE1 gene.

Authors:  Mehdi Agha Gholizadeh; Mina Mohammadi-Sarband; Fatemeh Fardanesh; Masoud Garshasbi
Journal:  BMC Med Genomics       Date:  2022-04-04       Impact factor: 3.063

2.  NMIHBA results from hypomorphic PRUNE1 variants that lack short-chain exopolyphosphatase activity.

Authors:  Harikiran Nistala; John Dronzek; Claudia Gonzaga-Jauregui; Shek Man Chim; Saathyaki Rajamani; Samer Nuwayhid; Dennis Delgado; Elizabeth Burke; Ender Karaca; Matthew C Franklin; Prasad Sarangapani; Michael Podgorski; Yajun Tang; Melissa G Dominguez; Marjorie Withers; Ron A Deckelbaum; Christopher J Scheonherr; William A Gahl; May C Malicdan; Brian Zambrowicz; Nicholas W Gale; Richard A Gibbs; Wendy K Chung; James R Lupski; Aris N Economides
Journal:  Hum Mol Genet       Date:  2021-01-06       Impact factor: 6.150

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.